- Home
- HURA vs ACHV Comparison
HURA vs ACHV Comparison
Compare HURA & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- ACHV
- Stock Information
- Founded
- HURA 2009
- ACHV N/A
- Country
- HURA United States
- ACHV United States
- Employees
- HURA N/A
- ACHV N/A
- Industry
- HURA
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HURA
- ACHV Health Care
- Exchange
- HURA Nasdaq
- ACHV Nasdaq
- Market Cap
- HURA 122.0M
- ACHV 131.2M
- IPO Year
- HURA N/A
- ACHV N/A
- Fundamental
- Price
- HURA $3.06
- ACHV $2.55
- Analyst Decision
- HURA Strong Buy
- ACHV Strong Buy
- Analyst Count
- HURA 2
- ACHV 3
- Target Price
- HURA $11.50
- ACHV $14.33
- AVG Volume (30 Days)
- HURA 773.7K
- ACHV 652.7K
- Earning Date
- HURA 08-14-2025
- ACHV 08-07-2025
- Dividend Yield
- HURA N/A
- ACHV N/A
- EPS Growth
- HURA N/A
- ACHV N/A
- EPS
- HURA N/A
- ACHV N/A
- Revenue
- HURA N/A
- ACHV N/A
- Revenue This Year
- HURA N/A
- ACHV N/A
- Revenue Next Year
- HURA N/A
- ACHV N/A
- P/E Ratio
- HURA N/A
- ACHV N/A
- Revenue Growth
- HURA N/A
- ACHV N/A
- 52 Week Low
- HURA $1.80
- ACHV $1.84
- 52 Week High
- HURA $8.63
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- ACHV 46.32
- Support Level
- HURA N/A
- ACHV $2.37
- Resistance Level
- HURA N/A
- ACHV $2.56
- Average True Range (ATR)
- HURA 0.00
- ACHV 0.12
- MACD
- HURA 0.00
- ACHV 0.01
- Stochastic Oscillator
- HURA 0.00
- ACHV 47.37
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.